Lazard SF Healthcare
Can anyone provide info on: sectors covered, recent deals, analyst program, reputation, etc. Also previous interview experience.
Trending Content
Career Resources
WSO Free Modeling Series - Now Open Through
June 30, 2024
9 Free Financial Modeling Lessons
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
+Bonus: Get 27 financial modeling templates in swipe file
+Bonus: Get 27 financial modeling templates in swipe file
Did you try looking at the company database for any interview reviews, there's a lot in there
Lazard HC SF (Originally Posted: 09/14/2013)
Anybody know anything about this group?
Deal Flow/Hours/Exit Opps/Culture
Any info would be appreciated
Deal Flow: They advised Amgen on their $10B acquisition of Onyx within the last few weeks. See the link below. If it's one of the 5 biggest biotech deals in history as the article says, that's not bad.
http://dealbook.nytimes.com/2013/08/25/amgen-to-buy-onyx-pharmaceutical…
Hours/Culture: Shorter hours and more laid back than probably any NY office and some SF offices too, but it's still IB.
Exit Opps: Hard to say. I tend to think that if you're a top analyst at a top tier firm, regardless of the office, you should be in good shape.
Thanks Bolt, appreciate the feedback.
Thanks Bolt, appreciate the feedback.
I thought it was really sweaty? Might be somewhat outdated information though.
bumping this - would appreciate any recent information on the above!
The Lazard healthcare group is pretty small and split b/w SF that does mostly biotech/life sciences and NY which does more hospital administration, insurance, IT etc.
Even though the division is small, they punch way above their weight class; they've worked on some large deals and have great deal flow. Exits in healthcare banking aren't the typical exits in generalist banking, but Laz SF places very well into top venture capital firms (i.e. NEA) and industry
would you say the lack of typical buyout HC PE exits is more self-selection? Given how early on-cycle is I'm sure people working exclusively on biopharma could still recruit for buyout HC PE; moreover, I've seen people recruit for buyout PE in industries that are very different to their group (eg. seen a Natural Resources kid go to Tech Buyout PE) - largely bc of the lack of real deal experience when going through on cycle
Distinctio maiores ullam eveniet et ut voluptatem dicta. Tempore quia autem quia saepe et nesciunt. Nihil quia sit ipsam dolor. Mollitia ut et iusto minima et.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...